期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 6, 期 5, 页码 202-209出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758834014539183
关键词
ado-trastuzumab emtansine; antibody-drug conjugate; breast cancer; T-DM1; HER2
类别
资金
- Conquer Cancer Foundation of the American Society of Clinical Oncology
- National Cancer Institute of the National Institutes of Health [P30CA016042]
In February 2013, ado-trastuzumab emtansine (T-DM1, Kadcyla (R)) received regulatory approval in the United States for treatment-refractory human epidermal growth factor receptor 2 (HER2) positive metastatic or locally advanced breast cancer based on results from EMILIA, a large phase III trial that compared standard of care lapatinib plus capecitabine to T-DM1. Several other studies have been reported in the metastatic setting and multiple trials are ongoing or planned in the neoadjuvant, adjuvant and advanced disease settings. Here we provide an updated and comprehensive review of clinical trials evaluating T-DM1, discuss management of toxicity associated with this drug, propose potential mechanisms of resistance and offer practical considerations for the treating oncologist.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据